Before COVID-19, Moderna was in danger of hemorrhaging investors, as persistent safety concerns and other doubts about its mRNA delivery system threatened its entire product pipeline. Fear caused by the pandemic crisis made those concerns largely evaporate, even though there is no proof that they were ever resolved. Those analyzing the COVID-19 crisis and its effects have mostly focused on how its disruptive nature has led to major shifts and recalibrations throughout society and the economy. Such disruption has also lent itself to a variety of agendas that had required an event of “reset” potential in order to be realized. In the case of the vaccine industry, COVID-19 has led to dramatic changes in how federal agencies manage the approval of medical countermeasures during a declared crisis, how trials for vaccine candidates are conducted, how the public perceives vaccination, and even how the term “vaccine” is defined.
If You Find EarthNewspaper.com Informative, Please Make A Contribution
Donate today and support the work I do seven days a week. Each day I publish more than a dozen news articles and videos, from honest, independent and reliable sources, on a completely ad-free website. There are four ways you may donate: credit card, check, bank wire, or SubscribeStar. I, Mark R. Elsis, thank you in advance for your gracious generosity, so that EarthNewspaper.com All The Honest News Fit To Publish may keep growing quickly.